Achillion (ACHN), Vertex (VRTX) Flying On Gilead's (GILD) '7977 Setback
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $548.05 +1.44%
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) is up 10 percent and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is surging over 20 percent in pre-open trading Friday following a major setback for Gilead Sciences (Nasdaq: GILD) Hep C treatment '7977.
The news is seen as a positive for both, as analysts at Baird explains "The derivative from this update is positive for VRTX, because on the margin it could/should extend Incivek's tail, and for ACHN, because its assets are complementary to nukes, nukes may need help in at least some populations, and uncertainty in the field is good for ACHN."
The news is seen as a positive for both, as analysts at Baird explains "The derivative from this update is positive for VRTX, because on the margin it could/should extend Incivek's tail, and for ACHN, because its assets are complementary to nukes, nukes may need help in at least some populations, and uncertainty in the field is good for ACHN."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Uber fined $966 Million in the Netherlands for automating driver suspensions - Reuters
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
Create E-mail Alert Related Categories
Analyst Comments, Momentum Movers, Trader TalkRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
